Update on Survival Outcomes With Long-Term Docetaxel in Metastatic Prostate Cancer
Posted: Monday, November 25, 2019
According to research presented at the European Society for Medical Oncology (ESMO) 2019 Congress (Abstract 844O), upfront docetaxel treatment significantly improved long-term survival outcomes for patients with metastatic hormone-naive prostate cancer, regardless of disease burden. “We advocate that upfront docetaxel is considered for both low-burden and high-burden metastatic patients,” concluded Nicholas D. James, PhD, of Queen Elizabeth Hospital, and colleagues.
The study followed up on the initial results of the STAMPEDE trial, which confirmed that upfront docetaxel treatment provided survival benefits in patients with prostate cancer who were beginning long-term androgen-deprivation therapy. A total of 724 patients treated with the standard of care and 362 patients treated with the standard of care plus docetaxel were evaluated at a median follow-up of 6.5 years. At the time of follow-up, 494 deaths had been reported in the standard-of-care group, with a median overall survival of 43.1 months. The group that received the standard of care plus docetaxel experienced an extended median overall survival of 59.1 months.
Treatment with docetaxel resulted in improved overall survival for patients with high-burden disease as well as those with low-burden disease (interaction P = .827). In addition, the standard of care plus docetaxel resulted in superior failure-free and progression-free survival for both burden subgroups when compared with the standard of care alone. No meaningful difference was noted in grade 3 to 5 toxicities occurring after 1 year between the treatment arms.
Disclosure: For full disclosures of study authors, visit esmo.org.